RIGEL PHARMACEUTICALS INC's ticker is RIGL and the CUSIP is 766559603. A total of 140 filers reported holding RIGEL PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.10 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $290,347 | -87.2% | 268,840 | -84.7% | 0.00% | -83.3% |
| Q2 2023 | $2,265,335 | -23.2% | 1,756,074 | -21.4% | 0.01% | -25.0% |
| Q1 2023 | $2,950,265 | +25.9% | 2,235,049 | +43.0% | 0.01% | +14.3% |
| Q4 2022 | $2,344,077 | +29.6% | 1,562,718 | +1.9% | 0.01% | +16.7% |
| Q3 2022 | $1,809,000 | +157.7% | 1,532,861 | +146.6% | 0.01% | +200.0% |
| Q2 2022 | $702,000 | -44.1% | 621,563 | +79.8% | 0.00% | -33.3% |
| Q3 2021 | $1,255,000 | -42.2% | 345,736 | -30.8% | 0.00% | -40.0% |
| Q2 2021 | $2,170,000 | -50.8% | 499,943 | -61.3% | 0.01% | -54.5% |
| Q1 2021 | $4,414,000 | +211.5% | 1,290,787 | +66.7% | 0.01% | +57.1% |
| Q2 2020 | $1,417,000 | +83.1% | 774,529 | +56.2% | 0.01% | +16.7% |
| Q1 2020 | $774,000 | -72.2% | 495,870 | -61.8% | 0.01% | -25.0% |
| Q4 2019 | $2,781,000 | +28.3% | 1,299,661 | +12.1% | 0.01% | +14.3% |
| Q3 2019 | $2,168,000 | -34.0% | 1,159,528 | -7.9% | 0.01% | -36.4% |
| Q2 2019 | $3,286,000 | -23.3% | 1,258,984 | -24.5% | 0.01% | -21.4% |
| Q1 2019 | $4,286,000 | +150.1% | 1,667,539 | +123.8% | 0.01% | +100.0% |
| Q4 2018 | $1,714,000 | -12.9% | 745,029 | +21.6% | 0.01% | +40.0% |
| Q3 2018 | $1,968,000 | +5.4% | 612,932 | -7.2% | 0.01% | -16.7% |
| Q2 2018 | $1,868,000 | +294.9% | 660,151 | +394.0% | 0.01% | +200.0% |
| Q1 2018 | $473,000 | -48.5% | 133,640 | -43.6% | 0.00% | -33.3% |
| Q4 2017 | $919,000 | +2452.8% | 236,765 | +1549.6% | 0.00% | – |
| Q3 2017 | $36,000 | -53.2% | 14,353 | -49.2% | 0.00% | – |
| Q2 2017 | $77,000 | -55.2% | 28,253 | -60.9% | 0.00% | -100.0% |
| Q4 2016 | $172,000 | -75.4% | 72,264 | -62.0% | 0.00% | -66.7% |
| Q3 2016 | $698,000 | +711.6% | 190,087 | +395.4% | 0.00% | – |
| Q2 2016 | $86,000 | -28.9% | 38,367 | -34.2% | 0.00% | -100.0% |
| Q1 2016 | $121,000 | -44.2% | 58,281 | -18.5% | 0.00% | 0.0% |
| Q4 2015 | $217,000 | +26.9% | 71,472 | +3.4% | 0.00% | 0.0% |
| Q3 2015 | $171,000 | -85.4% | 69,153 | -81.1% | 0.00% | -80.0% |
| Q2 2015 | $1,175,000 | +22.3% | 366,180 | +36.1% | 0.01% | 0.0% |
| Q1 2015 | $961,000 | +58.1% | 269,073 | +0.5% | 0.01% | +66.7% |
| Q4 2014 | $608,000 | +10.9% | 267,647 | -5.2% | 0.00% | +50.0% |
| Q3 2014 | $548,000 | -41.9% | 282,308 | +8.6% | 0.00% | -50.0% |
| Q2 2014 | $944,000 | -19.9% | 260,027 | -14.3% | 0.00% | -33.3% |
| Q1 2014 | $1,178,000 | -32.9% | 303,571 | -50.7% | 0.01% | -40.0% |
| Q4 2013 | $1,755,000 | – | 615,999 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CM Management, LLC | 1,500,000 | $1,620,000 | 1.72% |
| Soleus Capital Management, L.P. | 14,803,015 | $15,987,256 | 1.48% |
| ARMISTICE CAPITAL, LLC | 17,136,000 | $18,506,880 | 0.28% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,228,126 | $1,326,376 | 0.24% |
| GSA CAPITAL PARTNERS LLP | 971,441 | $1,049 | 0.09% |
| NJ State Employees Deferred Compensation Plan | 200,000 | $216,000 | 0.03% |
| Providence Wealth Advisors, LLC | 27,500 | $29,013 | 0.03% |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 1,151,765 | $1,243,906 | 0.03% |
| XTX Topco Ltd | 164,238 | $177,377 | 0.03% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 3,369,076 | $3,638,602 | 0.02% |